Travere Therapeutics (TVTX) Receivables (2014 - 2026)

Travere Therapeutics has reported Receivables for 13 years, with the latest figure at $88.5 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 142.59% year-over-year to $88.5 million; the trailing twelve-month figure through Mar 2026 stood at $88.5 million (up 142.59% YoY), and the FY2025 full-year result was $81.4 million, up 176.72% from the prior year.
• Receivables for Q1 2026 stood at $88.5 million, up from $81.4 million in the prior quarter.
• The five-year high for Receivables was $88.5 million in Q1 2026, with the low at $12.7 million in Q3 2022.
• Historically, Receivables has averaged $35.0 million across 5 years, with a median of $26.5 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables declined 5.45% — and 2025, when it surged 205.0%.
• Travere Therapeutics' Receivables stood at $18.5 million in 2022, then soared by 39.0% to $25.8 million in 2023, then gained by 14.11% to $29.4 million in 2024, then surged by 176.72% to $81.4 million in 2025, then increased by 8.72% to $88.5 million in 2026.
• The last three Receivables figures came in at $88.5 million (Q1 2026), $81.4 million (Q4 2025), and $84.5 million (Q3 2025), per Business Quant data.